Retail price regulation and innovation: Reference pricing in the pharmaceutical industry

Journal of Health Economics

Volumn 29, Issue 2, 2010, Pages 303-316

  Bardey, D ^a,b   Bommier, A ^b   Jullien, B ^b  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

^b TOULOUSE SCHOOL OF ECONOMICS   (France)

Author keywords

Innovation; Me too; Pharmaceutical laboratories; Reference pricing

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

DRUG; HEALTH EXPENDITURE; INDUSTRIAL REGULATION; INNOVATION; MODELING; PHARMACEUTICAL INDUSTRY; PRICING POLICY; RETAILING;

ARTICLE; DRUG COST; DRUG INDUSTRY; DYNAMICS; HEALTH CARE COST; HUMAN; MATHEMATICAL ANALYSIS; PHARMACEUTICAL CARE; WELFARE;

BIOMEDICAL RESEARCH; DRUG COSTS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; MODELS, ECONOMIC; MODELS, THEORETICAL;

FRANCE;

EID: 77950627391     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2009.11.015     Document Type: Article

References (21)

1. Aghion P., Tirole J. Opening the black box of innovation. European Economic Review 1994.
2. Anderson S., de Palma A., Thisse J. Discrete Choice Theory of Product Differentiation 1992, MIT Press.
3. Barro R., Sala-i-Martin X. Economic Growth 1995, MIT Press.
4. Berndt E.R., Cockburn I.M., Grepin K. The Impact of Incremental Innovation in Biopharmaceuticals: Drug Utilization in Original and Supplemental Indications 2006, mimeo MIT.
5. Brekke K., Konigbauer I., Straume O. Reference pricing of pharmaceuticals. Journal of Health Economics 2007, 26:613-642.
6. Brekke K., Kuhn M. Direct to consumer adverstising in pharmaceutical markets. Journal of Health Economics 2006, 25(1):102-130.
7. Danzon P.M. Reference pricing: theory and evidence. Reference Pricing and Pharmaceutical Policy 2001, Springer, New York. G. Lopez-Casasnovas, B. Jonsson (Eds.).
8. Danzon, P., Ketchman, J., 2004. Reference pricing of pharmaceuticals for medicare: evidence from Germany, the Netherlands and New Zeland, Frontiers in Health Policy Research 7:2, bepress.
9. Danzon, P., Liu, H., 1996. Reference pricing and physician drug budgets: the German experience in controlling pharmaceutical expenditures. Working paper, University of Pennsylvania.
10. Danzon P., Pauly M. Health insurance and the growth in pharmaceutical expenditures. Journal of Law and Economics 2002, XLV:587-613.
11. DiMasi J.A. New drug innovation and pharmaceutical industry structure: trends in the output of pharmaceutical firms. Drug Information Journal 2000, 34:1169-1194.
12. Dimasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003, 22:151-185.
13. Dimasi J.A., Hansen R.W., Grabowski H.G., Lasagna L. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 1991, 10(2):107-142.
14. DiMasi J.A., Paquette C. The economics of follow-on drug research and development. Pharmacoeconomics 2004, 22(Supl 2):1-14.
15. Dranove D., Metzler D. Do important drugs reach the market sooner. Rand Journal of Economics 1994, 25:402-422.
16. Gal-Or E. Exclusionary equilibria in health care markets. Journal of Economic and Management Strategy 1997, 5-43.
17. Gal-Or E. Mergers and exclusionary practices in health care markets. Journal of Economic and Management Strategy 1999, 315-350.
18. Hurwitz M., Caves R. Persuasion or information? Promotion and the shares of brand-name and generic pharmaceuticals. Journal of Law and Economics 1988, 31:299-320.
19. Laffont J.-J., Tirole J. A Theory of Incentives in Procurement and Regulation 1993, MIT Press.
20. Lopez-Casanovas G., Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000, 54:87-123.
21. O'Donoghue T., Scotchmer S., Thisse J. Patent breadth, patent life, and the pace technological progress. Journal of Economic and Management Strategy 1998, 7(1):1-32.